Every day in the U.S. 100 women die of metastatic breast cancer. Current clinical methods cannot determine from the primary site which tumors will metastasize and spread to other areas of the body. Herein, multiple imaging scales are used to assess the metabolic signatures of metastatic and dormant tumor cell lines. Fluorescence lifetime imaging microscopy (FLIM) and hyperpolarized magnetic resonance spectroscopy (hMRS) imaging studies are performed in 3D cell culture using an MRI compatible bioreactor and in vivo mouse models to evaluate metabolic signatures at the individual cellular and tumor mass scales to predict metastasis versus dormancy.
This abstract and the presentation materials are available to members only; a login is required.